Idebenone (Raxone(®)), a short-chain benzoquinone, is the only disease-specific drug approved to treat visual impairment in adolescents and adults with Leber's hereditary optic neuropathy (LHON), a rare genetic mitochondrial disease that causes rapid and progressive bilateral vision loss. The mechanism of action of idebenone involves its antioxidant properties and ability to act as a mitochondrial electron carrier. Idebenone overcomes mitochondrial complex I respiratory chain deficiency in patients with LHON by transferring electrons directly to mitochondrial complex III (by-passing complex I), thereby restoring cellular energy (ATP) production and re-activating inactive-but-viable retinal ganglion cells, which ultimately prevents further vision loss and promotes vision recovery. The approval of idebenone in the treatment of LHON was based on the overall data from a randomized clinical trial, a follow-up study and real-world data. Taken together, these studies provide convincing evidence that oral idebenone 900 mg/day for 24 weeks has persistent beneficial effects in preventing further vision impairment and promoting vision recovery in patients with LHON relative to the natural course of the disease. Therefore, idebenone is a valuable agent to treat visual impairment in adolescents and adults with LHON.
Brain. 2009 Sep;132(Pt 9):2317-26
[PMID:
19525327]
Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3112-5
[PMID:
19255150]
Brain. 2013 Feb;136(Pt 2):e230
[PMID:
23388409]
Curr Treat Options Neurol. 2011 Feb;13(1):109-17
[PMID:
21063922]
Brain. 2001 Jan;124(Pt 1):209-18
[PMID:
11133798]
Invest Ophthalmol Vis Sci. 2006 Dec;47(12):5303-9
[PMID:
17122117]
Brain. 2011 Sep;134(Pt 9):2677-86
[PMID:
21788663]
J Neuroophthalmol. 2012 Mar;32(1):54-7
[PMID:
22269948]
Arch Soc Esp Oftalmol. 2007 Jun;82(6):377-80
[PMID:
17573650]
Surv Ophthalmol. 2010 Jul-Aug;55(4):299-334
[PMID:
20471050]
Eur J Clin Pharmacol. 2009 May;65(5):493-501
[PMID:
19125241]
Orphanet J Rare Dis. 2014 Oct 23;9:158
[PMID:
25338955]
Ann Neurol. 2004 Nov;56(5):631-41
[PMID:
15505787]
Brain. 2011 Sep;134(Pt 9):e188
[PMID:
21810891]
PLoS One. 2011 Mar 31;6(3):e17963
[PMID:
21483849]
PLoS One. 2012;7(4):e36153
[PMID:
22558363]
Hong Kong Med J. 2014 Oct;20(5):451-4
[PMID:
25307075]
J Neurol. 2015 Dec;262(12):2776-9
[PMID:
26530508]
Brain. 2014 Feb;137(Pt 2):335-53
[PMID:
24369379]
Eye (Lond). 2014 May;28(5):521-37
[PMID:
24603424]
Cell Death Dis. 2015 Dec 17;6:e2021
[PMID:
26673666]
BMC Res Notes. 2011 Dec 22;4:557
[PMID:
22192149]
PLoS One. 2012;7(8):e42242
[PMID:
22879922]
Redox Biol. 2015;4:289-95
[PMID:
25625583]
J Neuroophthalmol. 2000 Sep;20(3):166-70
[PMID:
11001192]
J Neurol Sci. 1997 May 1;148(1):25-31
[PMID:
9125387]
J Neurol Neurosurg Psychiatry. 2001 Dec;71(6):813-6
[PMID:
11723211]
Graefes Arch Clin Exp Ophthalmol. 2006 Oct;244(10):1357-9
[PMID:
16523300]
J Neurol Sci. 1998 Oct 8;160(2):183-8
[PMID:
9849804]
PLoS One. 2012;7(9):e45182
[PMID:
23028832]
Vision Res. 1998 May;38(10):1495-504
[PMID:
9667014]
Biochim Biophys Acta. 2012 Feb;1817(2):363-9
[PMID:
22086148]
Chem Res Toxicol. 1998 Jan;11(1):54-63
[PMID:
9477226]
J Neurol. 2009 Mar;256 Suppl 1:31-5
[PMID:
19283348]
Lancet. 1992 Aug 8;340(8815):368-9
[PMID:
1353825]
J Neuroophthalmol. 2013 Mar;33(1):30-6
[PMID:
23263355]
Ophthalmic Genet. 2008 Mar;29(1):17-24
[PMID:
18363168]
Brain. 2011 Jan;134(Pt 1):220-34
[PMID:
20943885]
Antioxidants
Humans
Optic Atrophy, Hereditary, Leber
Randomized Controlled Trials as Topic
Ubiquinone
